Artivion (NYSE:AORT) Given New $30.00 Price Target at Lake Street Capital

Artivion (NYSE:AORT) had its price target hoisted by Lake Street Capital from $28.00 to $30.00 in a research note released on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock.

AORT has been the subject of a number of other research reports. Needham & Company LLC lifted their target price on shares of Artivion from $25.00 to $30.00 and gave the company a buy rating in a research note on Tuesday, May 7th. Stifel Nicolaus increased their price objective on Artivion from $22.00 to $25.00 and gave the stock a buy rating in a report on Tuesday, May 7th.

Artivion Trading Up 0.6 %

Shares of NYSE AORT opened at $25.61 on Tuesday. The company has a quick ratio of 4.26, a current ratio of 6.04 and a debt-to-equity ratio of 1.07. Artivion has a 12 month low of $12.16 and a 12 month high of $26.26. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -106.71 and a beta of 1.75. The business has a fifty day simple moving average of $23.12 and a 200-day simple moving average of $20.45.

Artivion (NYSE:AORT) last released its quarterly earnings results on Monday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04. Artivion had a negative net margin of 2.61% and a positive return on equity of 3.64%. The business had revenue of $97.43 million for the quarter, compared to analyst estimates of $92.30 million. Sell-side analysts predict that Artivion will post 0.24 EPS for the current year.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently added to or reduced their stakes in the company. Tidal Investments LLC bought a new position in Artivion in the first quarter worth $257,000. Price T Rowe Associates Inc. MD raised its stake in shares of Artivion by 5.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock valued at $713,000 after buying an additional 1,634 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of Artivion by 7.9% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 34,461 shares of the company’s stock valued at $729,000 after buying an additional 2,531 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Artivion by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after acquiring an additional 33,982 shares during the period. Finally, First Eagle Investment Management LLC boosted its position in shares of Artivion by 8.1% during the 1st quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock valued at $12,066,000 after acquiring an additional 42,705 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.